omniture
天境生物科技(上海)有限公司 IMab

Latest News

I-Mab Added to MSCI China Index

SHANGHAI and GAITHERSBURG, Md., May 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2021-05-13 20:00 3516

I-Mab Announces Upcoming Participation at May Conferences

SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-04-29 20:00 2598

I-Mab Filed 2020 Annual Report on Form 20-F

SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-04-28 20:00 1009

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2021-04-26 19:00 1019

I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

SHANGHAI and GAITHERSBURG, Md., March 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-03-03 21:00 4676

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-02-25 21:00 4127

I-Mab Announces Upcoming Participation at March Conferences

SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-02-24 21:00 4082

I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Feb. 10, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2021-02-10 21:00 4709

Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced

SHANGHAI and GAITHERSBURG, Md., Feb. 9, 2021 /PRNewswire/ -- A registered follow-on public offering...

2021-02-09 21:00 8810

Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2021-02-06 06:27 8510

I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage...

2021-02-05 21:00 5017

I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China

SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), ...

2021-02-04 21:00 4319

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), an...

2021-01-26 05:05 2610

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-12-23 21:00 5086

I-Mab Added to Nasdaq Biotechnology Index

SHANGHAI and GAITHERSBURG, Md., Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-12-14 21:00 7658

I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-12-04 21:00 7542

I-Mab Files Shelf Registration Statement for PIPE Investors

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-12-02 05:23 9021

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-12-01 21:00 2428

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020

SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-11-11 21:00 4493

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-11-09 21:12 3013
1234